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In this study, a polymeric lipid nanoparticle (NP) (simplified as Lipid NP) was reported as a
promising oral vaccine delivery system. The Lipid NPs composed of a hydrophobic poly-
meric poly(D,L-lactide-co-glycolide) (PLGA) core and a surface coating of lipid monolayer.
Membrane emulsification technique was used to obtain uniform-sized Lipid NPs. Oval-
bumin (OVA) was used as a model vaccine. Compared with the pure PLGA NPs, the Lipid
NPs achieved higher loading capacity (LC) and entrapment efficiency (EE) for the encap-
sulated OVA. An in vitro oral release profile showed that the OVA-Lipid NPs were with
lower initial burst and could protect the loaded OVA from the harsh gastrointestinal (GI)
environment for a long time. In addition, a humanmicrofold cell (M-cell) transcytotic assay
demonstrated that due to a lipid layer structure on the particle surface, the Lipid NPs
showed higher affinity to the M-cells. Since the M-cell in the intestinal epithelium played
an important role in particle transportation as well as intimately associated with they(D,L-lactide-co-glycolide); OVA, ovalbumin; LC, loading capacity; EE, entrapment efficiency;
, Peyer’s Patch; FAE, follicle-associated epithelial; HSPC, hydrogenated phosphatidylcholine;
ocarcinoma; DMEM, Dulbecco’s modified eagle’s medium; RPMI, Roswell park memorial
le; FITC, fluorescein isothiocyanate; UEA-1, ulex europaeus agglutinin-1; DCM, dichloro-
py; PBS, phosphate buffer; TEER, trans-epithelial electrical resistance; TEM, transmission
immunosorbent assay; HRP, horseradish peroxidase; TMB, tetramethylbenzidine; Ptm,
l dome; CLSM, confocal scanning microscopy.
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immune responses.
ª 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Oral delivery system is more preferred of vaccines for its
convenience, ease of pain, patient compliance, limited cross-
infection, and cost-effectiveness [1e6]. Importantly, the oral
route for vaccine delivery provides effective local mucosal
immunity [7]. Moreover, compared to injected vaccines, oral
immunity shows numerous of advantages, i) it is most effec-
tive for intestinal immune response [8,9], ii) it primesmucosal
aswell as systemic humoral and cellular immune systems [10]
by inducing the expression of homing receptors, iii) the oral
immunizations are able to generate the serum IgG and IgA
antibodies, because B cells activated in peripheral lymph
nodes cannot express mucosal homing receptors while B cells
activated inmucosa and draining lymph nodes tent to express
peripheral homing receptors [11].
Although the intestinal surfaces are enormous and antigen
presenting cells are considerably abundant in enteric mucosa,
the majority of vaccines in clinical application today are
administrated by intramuscularly or subcutaneously in-
jections. One explanation is that a relatively large dose of
vaccination is demanded and an immune tolerance is
accordingly induced for oral vaccination. One approach for
antigens surviving the GI tract and invading the mucosal
lymphoid tissues is to be entrapped into NPs or liposomes.
These particulate carriers are preferably transported into
Peyer’s Patch (PP) by M-cells and have been extensively used
in development of next generation of vaccines [12]. In general,
the intestinal tract composed of a single layer of tightly joined
epithelial cells prevents various microorganisms from pene-
trating into the host body [13], however, the M-cells on the
follicle-associated epithelial (FAE) of PP is noticeable by their
active transport feature. Compared with the regular enter-
ocytes, the M-cells are lack of surface and cellular enzymatic
activity but intimately interact with underlying immune cells
[14], making them particularly adapted to antigens trans-
cytosis. As a matter of fact, quantities of studies have been
focused on targeting M-cells to improve oral vaccination effi-
cacy and it has been reported that particles less than 1 mmand
adherent to M cells were most effectively taken up [15].
As drug delivery systems, the size control and size uni-
formity of carriers are very necessary because i) different size
of carriers will result in various profile in vitro including
encapsulation efficiency and release behavior, which will
further lead to different behavior in vivo including drug dis-
tribution and efficacy, ii) broad size distribution of carriers will
lead to poor repeatability of behavior in vitro and in vivo for
different batches, which will further result in difficult for
improvement in clinical use. Until now, many methods have
been developed to prepare polymer NPs including ultrasonic,homogenizer and double emulsionmethod. However, the NPs
prepared by these methods showed broad size distributions,
leading to poor repeatability of preparation and drug efficacy
in vitro for various batches.
In this study, we prepared polymeric Lipid NP as an oral
vaccine delivery system by membrane emulsification tech-
nique. The Lipid NPs were composed of hydrophobic polymer
core and stabilized by one layer of phospholipids embedded in
the surface area. These Lipid NPs are in a narrow size distri-
bution. Importantly, they combined all the desirable charac-
teristics of both polymeric NPs and liposomes, including
preventing incorporated vaccines from degradation,
enhancing their transmucosal absorption and possessing low
inherent toxicity as well.2. Materials and methods
2.1. Materials
Ovalbumin from chicken egg white was obtained from Sig-
maeAldrich (St. Louis, USA). PLGAwith a 75:25monomer ratio
and an acid end group was purchased from Lakeshore Bio-
materials (Birmingham, AL). Hydrogenated phosphatidylcho-
line (HSPC) of >98% purity based on dry weight was supplied
by Lipoid LLC (Newark, NJ). Polyvinyl alcohol (PVA) and
membrane were obtained from Kuraray Co., Ltd. (Tokyo,
Japan) and National Engineering Research Center for
Biotechnology (Beijing, China), respectively. The colon
adenocarcinoma (Caco-2) and Raji B lymphoblastoid cell lines
were provided by the Peking University Health Science Center
(Beijing, China). Dulbecco’s modified eagle’s medium (DMEM)
and the Roswell park memorial institute (RPMI) 1640 cell cul-
ture were purchased from Gibco (Grand Island, USA). 4,6-
Diamidino-2-phenylindole (DAPI) was obtained from Invi-
trogen (Grand Island, USA) and fluorescein isothiocyanate
(FITC)-conjugated ulex europaeus agglutinin-1 (UEA-1) was
purchased from SigmaeAldrich (St. Louis, USA). All other re-
agents were of analytical grade and commercially available.
6e8 weeks old female BALB/c mice were provided by Charles
River Laboratories (USA). All animal experiments were per-
formed in compliance with the institutional ethics committee
regulations and guidelines on animal welfare (Animal Care
and Use Program Guidelines of Peking University).
2.2. Preparation of OVA-loaded PLGA NPs and Lipid NPs
OVA-loaded PLGA NPs and Lipid NPs were prepared by a
combination of membrane emulsification and double emul-
sionesolvent evaporation method. The preparation process
was performed at room temperature. The OVA was used as a
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PLGAwas dissolved in 10ml dichloromethane (DCM) solution.
1 ml OVA aqueous solution (40 mg/ml) was added to the PLGA
DCM solution and followed by probe sonication (Branson,
USA) at 30% amplitude for 1min to obtain the water-in-oil (W/
O) emulsion. Then, it was added to 100ml PVA solution, gently
stirred and passed 5 times through a 0.8 mm pore size of
membrane at a nitrogen pressure of 2.0 MPa to obtain uniform
sized OVA loaded PLGA NPs. The remaining DCM was thor-
oughly evaporated by constantly stirring (150 rpm) for 4 h at
ambient conditions. The resulting OVA-PLGA NPs were
collected and washed 5 times by centrifugation at 10,000  g.
The final products were re-suspended and lyophilized, then
stored for future use.
For the OVA-loaded Lipid NPs preparation, the experi-
mental parameters were the same as the OVA-PLGA NPs,
except that the HSPC and PLGAwithmass ratio of 1:2 were co-
dissolved in 10 ml DCM solution (2.0, w/v), and 1 ml OVA
aqueous solution (40 mg/ml) was added to 10 ml HSPC/PLGA
DCM solution.
2.3. Characterization of the OVA loaded NPs
The average particle size and size distribution of the NPs in
each preparation were determined by dynamic light scat-
tering (Zetasizer Nano ZS, Malvern, UK). The obtained NPs
were dispersed in aqueous solution with a concentration of
1 mg/ml prior to lyophilization. Then, 1 ml of NPs suspension
was added in a sample cell for the measurements. Each
experimentwas performed in triplicate. A JSM-6700F scanning
electronmicroscopy (SEM, JEOL, Japan) was used to assess the
monodispersity, shape and surface morphology of the OVA-
loaded NPs. Accordingly, the samples were thoroughly dried,
and fixed onto a sample stage for coating with a gold layer
under vacuum. The SEM experiment was performed at an
acceleration voltage of 5 kV.
2.4. Determination of the LC and EE of OVA
The LC of the OVA was determined using the micro-BCA
method (Pierce Biotechnology, Rockford, IL). The lyophilized
NPswere dissolved in 50mMNaOHsolution at a concentration
of 100 mg/ml and incubated overnight at 4 C. The micro-BCA
experiments were performed according to the manufacturer
procedure. Blank NPs were used as controls and the LC and EE
values were calculated from Eqs. (1) and (2), respectively.
LCð%Þ ¼W1
W2
 100% (1)
EEð%Þ ¼W1
W3
 100% (2)
W1,W2 andW3 represented themass of encapsulated OVA,
the mass of overall NPs and the mass of initially added OVA,
respectively.
2.5. Evaluation of OVA release profiles
The loaded OVA release profilewas evaluated in vitro for 2 h in
0.1 M HCl, as the average gastric emptying time is about 2 h.Then pH 6.8 phosphate buffer (PBS) was used to test for OVA
release for 3 h, as the average small intestinal transit time is
about 3 h. Next, the dissolutionmediumwas replacedwith pH
7.4 PBS. The samples were centrifuged (10,000  g) for 5 min.
The supernatants were then collected tomonitor the amounts
of OVA released from the NPs using the micro-BCA method
described above.
2.6. In vitro M-cell assay
The in vitro human M-cell model was constructed referred to
a previously described procedure [16] with some modifica-
tions. Briefly, the Caco-2 cells and Raji B cells were co-cultured
in 12 mm Transwell system (Corning Costar 3402#, NY, USA).
4.0  105 of Caco-2 cells suspended in DMEM were seeded on
the upper side of Transwell, and cultivated for 14 days to form
confluent monolayers. Then, 6.0  105 of Raji B cells sus-
pended in RPMI:DMEM (v:v, 1:2) were added to the lower
chamber, and the co-culture was maintained for 6 days. Fresh
medium was given in every 24 h during cell culture. For vali-
dation of M-cell model construction, the trans-epithelial
electrical resistance (TEER) with Caco-2 cells and M-cells
were monitored and the morphological changes of M-cells
were compared with Caco-2 monolayer culture from the ver-
tical micro-section of each cell layer using transmission
electron microscope (TEM, JEOL, Tokyo, Japan).
For the NPs transcytosis evaluation, 100 mg PLGA NPs or
Lipid NPs suspended in 0.5 ml PBS were added to the upper
side of the Transwell insert. At pre-determined time intervals
(0.5, 1, 2, and 3 h), the samples from the lower chamber were
collected. The transported signals (%) were calculated by the
fluorescent intensity of the samples.
2.7. Vaccinations and measurements of IgG and IgA
antibody titers
The immune effects of OVA alone, OVA-PLGA NPs and OVA-
Lipid NPs were analyzed in female BALB/c mice (6e8 weeks
old). Themicewere divided into three cohorts of eight animals
each. All cohorts were treated twice during weeks 0 and 2. The
groups were treated via oral administration with 100 ml OVA,
OVA-PLGA NPs and OVA-Lipid NPs suspended in 9% (w/v)
sucrose solution loaded with 100 mg OVA. Blood samples and
intestinal wash samples were collected on day 35 and stored
at 20 C for IgG and IgA titer analysis [17].
The antibody titers were tested via enzyme-linked immu-
nosorbent assay (ELISA) using 96-well microtiter plates. The
plates were loaded with 100 ml of OVA (20 mg/ml in 0.05 M
carbonate buffer, pH 9.6), incubated overnight at 4 C and
washed five times with a solution of Tween 20 (0.05% v/
v)þ PBS (pH 7.4, PBST). The plates were thenwashedwith BSA
(0.5%) containing PBST to prevent non-specific binding to the
antibodies. Two-fold serial dilutions of the sampleswere done
in PBS and the samples were added to the plates. The plates
were then incubated for 2 h at room temperature and washed
thoroughly as before. A volume of 100 ml of goat anti-mouse
IgG horseradish peroxidase (HRP) conjugate, diluted to 1/
20,000 in PBS, was then added to eachwell and the plates were
again incubated for 2 h at room temperature and washed as
before. A 100 ml volume of the enzyme substrate 3,30,5,50-
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reaction was stopped after 15min with 50 ml of 2 M H2SO4. The
optical density (OD) at 450 nmwas measured using an Infinite
M200 microplate reader (Tecan, Switzerland) and IgG titers of
samples were calculated using a dilution with an OD 0.1. An
ELISA was done as above for analysis of IgA titers except that
the anti-mouse IgA HRP conjugate was diluted to 1/50,000 in
the PBST solution.3. Results and discussion
3.1. Particle size and size distribution
We prepared PLGA NPs and Lipid NPs using membrane
emulsification technique to evaluate if the lipid layer on the
particle surface could influence the particle size. The pore size
of the membrane was 0.8 mm and the trans-membrane pres-
sure (Ptm) was 2.0 MPa. PVA solution with concentration of
0.1% was used as a stabilizer in the external water phase. As
shown in Table 1, all the produced NPs were in a narrow size
distribution (PDI below 0.1). The small differences in size be-
tween the different batches of NPs demonstrated the good
reproducibility in the method of preparation used. Compared
with the PLGA NPs, the Lipid NPs which prepared with the
same experimental parameters showedmuch smaller particle
size. This result suggested that during the formation of the
Lipid NPs, the lipid molecules could act as co-emulsifier to
reduce the particle size.
It should be mentioned that PVA acted as a stabilizer in
external water phase and the concentration of PVA played an
important role in affecting the size of the NPs. If 0.1% (w/v)
PVA was used as described above, the self-assembled lipid
molecules in the oil/water interface could act as co-emulsifier
to significantly reduce the particle size. However, if 2.0% (w/v)
PVA was used, the PLGA NPs and Lipid NPs were with the
similar particle size.
Ptm has a crucial effect on the particle size distribution
using the membrane emulsification method. Basically, the
shear stress on the pre-emulsion droplets was increased by
increasing the Ptm. If the Ptm was too high, the emulsions
were forced to pass through the pore channels on the wall of
the membrane by acute friction, leading to rather small NPs.
However, with a relatively low pressure, the large droplets had
difficulty in passing through the membrane pores. In such a
case, the emulsion droplets would slowly change their shapes
in the pore channel instead of breaking down into small
uniform-sized droplets. Under most experimental conditions,Table 1 e Particle size and size distribution.
Formulation Diameter (nm) Size distribution (PDI)
Lipid NPs 205.3  4.7 0.029  0.020
PLGA NPs 528.5  6.6 0.019  0.014
OVA-Lipid NPs 215.3  3.5 0.048  0.018
OVA-PLGA NPs 558.2  16.5 0.045  0.011
All the formulations were produced using 0.1% (w/v) PVA solution
as external water phase. Statistical data analyses were performed
using mean value with S.D.; n ¼ 3.an unsuitable Ptm contributed to a broad size distribution.
The optimal Ptm generally depended on the characteristics of
the carrier system and the viscosity of the pre-emulsion.
3.2. Morphology of PLGA NPs and Lipid NPs
SEM experiment was used to gain an understanding of the
morphology and size distribution of OVA-loaded PLGA NPs
and Lipid NPs. To eliminate the particle size effects, the PLGA
NPs were prepared using 2.0% (w/v) PVA solution to become
the similar size as the Lipid NPs. As shown in Fig. 1, both the
PLGA NPs and Lipid NPs were in a narrow size distribution.
PLGA NPs were spherical in shape with a comparatively
smooth surface (Fig. 1A). By contrast, the surface texture of the
Lipid NPs was relatively uneven (Fig. 1B). These morphology
differences were mainly attributed to that the prevention of
the polymer hydrophobic bones from exposure to the external
aqueous solution leading to a dense structure of the PLGA NPs
[18,19]. As to the Lipid NPs, there were strong interactions
between the lipids hydrophobic tails and PLGA blocks. Given
these two components differed in their hydrophilicity/hy-
drophobicity, there was a re-arrangement of polymers blocks
at the oil/water interface during the organic reagent extrac-
tion. The circular depressions on the particle surfacemight be
formed when the external water droplets were inverted and
encapsulated within the oil phase [20].
3.3. LC and EE with OVA-PLGA NPs and OVA-Lipid NPs
The LC and EE represent the percentage of loaded OVA to the
overall particles and entrapped OVA to the initial OVA,
respectively. They are mainly affected by the preparation
conditions, copolymer compositions, particle sizes and char-
acterization methods [21]. The loss of vaccines is mainly due
to the water channels between the internal and external
phase allowing the soluble vaccines to diffuse through con-
centration gradient [22]. We prepared OVA-PLGA NPs and
OVA-Lipid NPs and examined the differences of LC and EE
between them. To eliminate the particle size effects, the PLGA
NPs were prepared using 2.0% (w/v) PVA solution to become
the similar size as the Lipid NPs. The LC and EE for OVA-PLGA
NPs were only 8.4  0.6% (w/w) and 50.3  3.6% (w/w),
respectively. As to the OVA-Lipid NPs, the LC and EE were
equal to 15.9  0.8% (w/w) and 95.3  4.8% (w/w), respectively.
It could be concluded that the lipid layer structure made the
Lipid NPs more efficient in OVA loading. In our point of view,
the lipid layer was supposed to protect the loaded OVA in two
ways, i) during the formation of the pre-emulsion, the lipid
molecules prevented the OVA fromdiffusing out, ii) in order to
remove any trace of organic reagents, a long-term evaporation
was generally required [23], resulting in a further waste of
soluble vaccines, while the lipid layer kept the carried proteins
from fluxing to the external phase.
3.4. Release profiles of OVA-PLGA NPs and OVA-Lipid
NPs
The cumulative release profiles of OVA-PLGA NPs and OVA-
Lipid NPs were shown in Fig. 2. After 5 h of incubation in GI
medium, 58.5  0.8% of OVA was released from PLGA-NPs. By
Fig. 1 e SEM observations of PLGA NPs (A) and Lipid NPs (B) with the similar particle size. Scale bars represent 1 mm.
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GI medium. Moreover, following the polymer matrix erosion,
both types of OVA-loaded NPs slowly released reaching 80% at
60 h. According to this, pH release dependence was evidenced
for PLGA NPs and Lipid NPs. Comparedwith the PLGANPs, the
Lipid NPs with lipid-shell structure could more effectively
shield the loaded OVA in gastric conditions and restrain the
external water penetrating through the water channels.3.5. Characterization of in vitro M-cell model
M-cells are specialized intestinal epithelial cells which inti-
mately associated with underneath immune cells in the FAE
of PP. Moreover, it has been reported that most of the partic-
ulate carriers are trans-located to the subepithelial dome
(SED) by M-cell transcytosis. In this point of view, an in vitro
M-cell model is important to evaluate the characteristics of
the vaccine delivery system. In this study, we constructed the
M-cell model by cultivation of Caco-2 cells and Raji B lym-
phocytes in reference to a previous study [16,24]. To confirm
whether the in vitro M-cell model was well developed, we
monitored the TEER of both Caco-2 cells and Caco-2/Raji B co-
cultured cells from 14 to 20 days of incubation. At day 14, the
TEER of the Caco-2monolayer was greater than 300 U cm2 and
continually increased during the next 6 days of incubation. By
contrast, as to the Caco-2/Raji B co-cultured cells, after the Raji
B cells were added into the Transwell system, the TEER was
initially reduced and then maintained to approximately
300 U cm2. This result indicated a conversion from Caco-2 cell
to M-cell model. In addition, after 20 days of incubation, weFig. 2 e In vitro cumulative release profiles for OVA-PLGA
NPs and OVA-Lipid NPs. Statistical data analyses were
performed using mean value with S.D.; n [ 3.used TEM to observe the vertical micro-sections of both Caco-
2 and M-cell layers. As shown in Fig. 3A, Caco-2 cell developed
well organized brushes. By contrast, with Raji B cells inducing
in lower chamber, the M-cell basolateral membrane was
invaginated (Fig. 3B) and a large “pocket” was formed. In the
intestine, M-cell generally formed this “pocket” to allow the
migration of immune cells. The TEER and TEM results together
supported the conversion from Caco-2 cell to M-cell.3.6. Transcytotic efficiency towards PLGA NPs and Lipid
NPs
The PLGANPs and Lipid NPswith the similar particle sizewere
prepared to explore their affinity with human M-cell model.
Briefly, Cy3 stained fluorescent PLGA NPs or Lipid NPs were
seeded in the upper side of the Transwell. At pre-determined
time intervals, we collected the samples in the lower chamber
and assessed the fluorescent intensity of the samples to
calculate the transported signals (%) towards PLGA NPs or
Lipid NPs. As shown in Fig. 4A, during the 3 h of incubation,
there were more Lipid NPs transported across M-cell layer
than PLGA NPs. At 3 h, the accumulated amount of Lipid NPs
fluorescent signals were almost 1.5-fold higher than the PLGA
NPs. After the incubation, we used the confocal scanning
microscopy (CLSM) to observe whether the enhancement of
transcytotic efficiencywith Lipid NPswould be due to increase
of specific M-cell affinity resulted by lipid layer. As shown in
Fig. 4B, cell nucleus stained with DAPI, M-cell layers stained
with FITC-UEA-1 and NPs stained with Cy3 were observed in
blue, green and red fluorescent signals, respectively. The
FITC-UEA-1was used to label the unique signature L-fucose on
M-cells and the green fluorescent signals (Fig. 4B) indicated
the formation of M-cells. From the merge images observation,
Lipid NPs more effectively (more red signals) bound to the
in vitro human M-cell model. This result, together with the
above transported efficiency assay supported that the Lipid
NPswith lipid layer onNP surface showed higher affinity toM-
cell layer than PLGA NPs and could be subsequently trans-
ported by the M-cell layer.3.7. Mucosal and systemic immune responses
In this study, the immune responses elicited towards an oral
vaccination system based on PLGA NPs and Lipid NPs con-
taining a model vaccine OVA were measured. The rationale
Fig. 3 e TEM observation of the vertical micro-section of the Caco-2 and M-cell layer. (A) Caco-2 cell layer developed well-
organized brushes. Scale bars indicate 0.5 mm. (B) The brushes of M-cell layer were de-organized and a large “pocket” was
formed. Scale bars indicate 2 mm.
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NP surface to bemore taken up by the intestinal epithelia. 6e8
weeks old female BALB/c mice were orally administrated with
OVA alone, OVA-PLGA NPs and OVA-Lipid NPs, respectively.
After 35 days of vaccination, we monitored the IgG antibody
titers from serum sample and IgA antibody titers from intes-
tinal wash sample, respectively. The IgG and IgA antibodies
represented humoral and mucosal immune responses in our
work. As shown in Fig. 5, oral administration of OVA alone
produced the lowest humoral and mucosal immune response
during the 35 days of vaccination. In comparison to the OVAFig. 4 e Transcytotic efficiency of PLGA NPs and Lipid NPs with
transported signals towards PLGA NPs and Lipid NPs. Statistical
n [ 3. (B) CSLM observations of the affinity effects between PLG
fluorescent signals represent cell nucleus, M-cell and Cy3 stainalone, the OVA-PLGA NPs showed higher IgG and IgA titers.
This result mainly attributed to that i) the PLGA NPs protected
the entrapped OVA from hash GI environment and main-
tained the bioactivity of the vaccine, ii) the NPs performed as a
“reservoir” allowing sufficient vaccines to induce immune
responses. In addition, compared with orally administrated
with OVA alone and OVA-PLGA NPs, the OVA-Lipid NPs
induced the most effective immune responses in both hu-
moral and mucosal immune system. One possible explana-
tion was that the Lipid NPs could load more OVA inside the
particle and more effectively protect them from the harsh GIin vitro human M-cell model. (A) Time-dependent
data analyses were performed using mean value with S.D.;
A NPs and Lipid NPs with M-cell layer. Blue, green and red
ed NPs, respectively. Scale bars represent 100 mm.
Fig. 5 e Serum IgG (A) and mucosal IgA (B) antibody responses to the BALB/c mice with orally vaccinated with OVA alone,
OVA-PLGA NPs and OVA-Lipid NPs, respectively. Each column represented mean with S.D. (*P< 0.05, **P< 0.01,
***P< 0.001, one-way ANOVA with Tukey post-test; n [ 8).
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more Lipid NPs to the underneath immune cells and elicit
efficient immune responses. The in vivo vaccinations proved
that the Lipid NP could potentially be used as a high perfor-
mance carrier for oral vaccine delivery.4. Conclusion
In this study, we have developed homogeneous PLGA-Lipid
NPs for oral delivery of vaccines. The Lipid NPs were produced
bymembrane emulsification combined with double-emulsion
method. Compared with the pure PLGA NPs, the Lipid NPs
achieved higher LC and EE for the encapsulated OVA. The
in vitro oral release showed that the Lipid NPwas effectively in
sustained and controlled release for oral delivery of vaccines.
Moreover, the in vitro M-cell assay demonstrated that the
Lipid NPs showed higher affinity to theM-cells than PLGANPs.
Since the M-cells are crucial in particle translation as well as
intimately associated with the underlying immune cells, the
OVA-Lipid NPs effectively induced high level of IgG and IgA
antibody responses. These results together supported that the
Lipid NPs developed in our study could be used as a promising
carrier for oral delivery of vaccines.
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